No more eye drops for glaucoma! There is a the new treatment with medication directly placed inside the eye.
Bimatoprost (Lumigan™) and Travoprost (Travatan™) are currently being tested as intraocular inserts. Both inserts release the medication for about six months, showing a great effect in the reduction of elevated intraocular pressure in patients with glaucoma.
The two inserts for glaucoma currently undergoing investigation in the USA are sponsored by ForSight VISION5 (Menlo Park, California) and Glaukos (Laguna Hills, California). Most likely, this new treatment for glaucoma will become available in 2017.
The clinical trial with the Bimatoprost insert (Helios insert) is currenty at the end of phase two and has enrolled 130 patients with primary open angle glaucoma. Constant and prolonged intraocular pressure drop has been observed through a six months period comparable to timolol 0.5% eye drops twice daily.
We will post all updated clinical trial results and offer this promising new treatment strategy as soon as efficacy and safety will be confirmed by more advanced investigations.